通过对六个独立队列的元分析,预测晚期膀癌的免疫治疗反应
Lilian Marie Boll1, Sergio Vázquez Montes de Oca1, Marta E Camarena1
1Hospital del Mar Research Institute (HMRIB), Barcelona, Spain.
Nature communications
|February 20, 2025
概括
预测晚期膀癌中对免疫检查点抑制剂 (ICI) 的反应是具有挑战性的. 这项研究确定了瘤突变负担,APOBEC签名和巨细胞丰富度是免疫治疗有效性的关键预测因素.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 晚期膀癌中对免疫检查点抑制剂 (ICI) 的反应非常可变.
- 对于免疫疗法疗效的预测生物标志物至关重要.
研究的目的:
- 为治疗抗PD-1/抗PD-L1治疗的晚期膀癌患者开发准确的预测模型.
- 确定与治疗反应相关的关键分子和细胞因素.
主要方法:
- 整合了来自707名晚期膀癌患者的突变和基因表达数据.
- 开发免疫治疗反应的预测模型.
- 免疫细胞透和突变特征的分析.
主要成果:
- 瘤突变负担 (TMB),APOBEC突变特征丰富度和亲炎性巨细胞的丰富性是响应的重要预测因素.
- 高免疫透率并不总是与更好的反应相关,通常是由于免疫抑制机制.
- 在非免疫透亚型中确定了特定的预测变量.
结论:
- 这项研究为预测晚期膀癌免疫治疗反应提供了新的见解.
- 这些发现支持对膀癌患者的精准医学策略的推进.
- 已识别的生物标志物可以指导治疗决策并改善患者的治疗结果.
相关概念视频
01:27Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K